Marinus Pharma Analyst Ratings
Marinus Pharmaceuticals Price Target Cut to $1.00/Share From $3.00 by RBC Capital
Oppenheimer Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
A Quick Look at Today's Ratings for Marinus Pharmaceuticals(MRNS.US), With a Forecast Between $3 to $3
Marinus Downgraded After Setback to Late-stage Trial
Marinus (MRNS) Receives a Hold From RBC Capital
Marinus Pharmaceuticals Downgraded to Neutral From Buy at H.C. Wainwright
Marinus Pharmaceuticals Cut to Market Perform From Market Outperform by JMP Securities
Marinus Pharmaceuticals Downgraded to Hold From Buy at Truist
Marinus Pharma Analyst Ratings
Marinus Pharma Analyst Ratings
A Quick Look at Today's Ratings for Marinus Pharmaceuticals(MRNS.US), With a Forecast Between $6 to $10
Marinus Pharma Analyst Ratings
Truist Financial Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
Marinus Pharmaceuticals Price Target Maintained With a $13.00/Share by Cantor Fitzgerald
Cautious Optimism Amidst Clinical Uncertainties: A Hold Rating for Marinus Pharmaceuticals
A Quick Look at Today's Ratings for Marinus Pharmaceuticals(MRNS.US), With a Forecast Between $11 to $11
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $11 Price Target
A Quick Look at Today's Ratings for Marinus Pharmaceuticals(MRNS.US), With a Forecast Between $3 to $11
Marinus Pharma Analyst Ratings
No Data
No Data